You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMifepristone
Accession NumberDB00834  (APRD00432)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome [PubChem]. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Structure
Thumb
Synonyms
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
Corlux
Mifegyne
Mifeprex
Mifepriston
Mifepristona
Mifépristone
Mifepristonum
RU-486
RU486
External Identifiers
  • RU-38486
  • RU-486
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Korlymtablet300 mg/1oralCorcept Therapeutics Inc2012-02-17Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CorluxCorcept Therapeutics Incorporated
MefipilAbbott
MifegyneExelgyn Laboratories
MifeprexDanco Laboratories
Brand mixtures
NameLabellerIngredients
MifegymisoLinepharma International Limited
SaltsNot Available
Categories
UNII320T6RNW1F
CAS number84371-65-3
WeightAverage: 429.5937
Monoisotopic: 429.266779369
Chemical FormulaC29H35NO2
InChI KeyInChIKey=VKHAHZOOUSRJNA-GCNJZUOMSA-N
InChI
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
IUPAC Name
(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1,6-dien-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[[email protected]](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassOxosteroids
Direct ParentOxosteroids
Alternative Parents
Substituents
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • Substituted aniline
  • Dialkylarylamine
  • Aniline
  • Benzenoid
  • Ynone
  • Monocyclic benzene moiety
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
PharmacodynamicsMifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.
Mechanism of actionThe anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
Related Articles
AbsorptionThe absolute bioavailability of a 20 mg oral dose is 69%
Volume of distributionNot Available
Protein binding98% (bound to plasma proteins, albumin and a 1-acid glycoprotein)
Metabolism

Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17–propynyl chain.

Route of eliminationFecal: 83%; Renal: 9%.
Half life18 hours
ClearanceNot Available
ToxicityNearly all of the women who receive mifepristone will report adverse reactions, and many can be expected to report more than one such reaction. About 90% of patients report adverse reactions following administration of misoprostol on day three of the treatment procedure. Side effects include more heavy bleeding than a heavy menstrual period, abdominal pain, uterine cramping, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7135
Caco-2 permeable+0.6716
P-glycoprotein substrateSubstrate0.643
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7606
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.8334
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.6293
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6129
Ames testNon AMES toxic0.856
CarcinogenicityNon-carcinogens0.825
BiodegradationNot ready biodegradable0.9971
Rat acute toxicity2.7705 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9177
hERG inhibition (predictor II)Non-inhibitor0.6879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Danco laboratories llc
Packagers
  • Danco Labs LLC
Dosage forms
FormRouteStrength
Tabletoral300 mg/1
Kit; tabletbuccal; oral
Prices
Unit descriptionCostUnit
Mifeprex 200 mg tablet90.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8921348 No2008-08-272028-08-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191-196 °CFDA Label
water solubilityPoorly solubleFDA Label
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00336 mg/mLALOGPS
logP5.33ALOGPS
logP5.13ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)12.87ChemAxon
pKa (Strongest Basic)4.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity132.58 m3·mol-1ChemAxon
Polarizability50.71 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Narendra Joshi, Anil Khile, Nitin Pradhan, “Novel polymorph form M of mifepristone and process for its preparation.” U.S. Patent US20070105828, issued May 10, 2007.

US20070105828
General References
  1. Fiala C, Gemzel-Danielsson K: Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006 Jul;74(1):66-86. Epub 2006 May 19. [PubMed:16781264 ]
  2. Heikinheimo O, Kekkonen R, Lahteenmaki P: The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception. 2003 Dec;68(6):421-6. [PubMed:14698071 ]
  3. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005 May-Jun;11(3):293-307. Epub 2005 Mar 24. [PubMed:15790602 ]
  4. Spitz IM, Bardin CW, Benton L, Robbins A: Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998 Apr 30;338(18):1241-7. [PubMed:9562577 ]
  5. Piaggio G, von Hertzen H, Heng Z, Bilian X, Cheng L: Meta-analyses of randomized trials comparing different doses of mifepristone in emergency contraception. Contraception. 2003 Dec;68(6):447-52. [PubMed:14698075 ]
External Links
ATC CodesG03XB51G03XB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (46.5 KB)
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe therapeutic efficacy of 4-Androstenedione can be decreased when used in combination with Mifepristone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Mifepristone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Mifepristone.
AcarboseAcarbose may increase the hypoglycemic activities of Mifepristone.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Mifepristone.
AceclofenacThe serum concentration of Aceclofenac can be increased when it is combined with Mifepristone.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Mifepristone.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Mifepristone.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Mifepristone.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Mifepristone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Mifepristone.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Mifepristone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Mifepristone.
AicarAicar may increase the hypoglycemic activities of Mifepristone.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Mifepristone.
AlclometasoneThe therapeutic efficacy of Alclometasone can be decreased when used in combination with Mifepristone.
AldosteroneThe therapeutic efficacy of Aldosterone can be decreased when used in combination with Mifepristone.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Mifepristone.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Mifepristone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Mifepristone.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Mifepristone.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Mifepristone.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Mifepristone.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Mifepristone.
AlogliptinAlogliptin may increase the hypoglycemic activities of Mifepristone.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Mifepristone.
AlosetronThe metabolism of Alosetron can be decreased when combined with Mifepristone.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Mifepristone.
AmantadineMifepristone may increase the QTc-prolonging activities of Amantadine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Mifepristone.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Mifepristone.
AmcinonideThe therapeutic efficacy of Amcinonide can be decreased when used in combination with Mifepristone.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Mifepristone.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Mifepristone.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Mifepristone.
AmiodaroneMifepristone may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Mifepristone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Mifepristone.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Mifepristone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Mifepristone.
AmoxapineMifepristone may increase the QTc-prolonging activities of Amoxapine.
AmoxapineAmoxapine may increase the hypoglycemic activities of Mifepristone.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Mifepristone.
AnagrelideMifepristone may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Mifepristone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Mifepristone.
ApomorphineMifepristone may increase the QTc-prolonging activities of Apomorphine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Mifepristone.
AprepitantThe serum concentration of Mifepristone can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Mifepristone.
Arachidonic AcidThe serum concentration of Arachidonic Acid can be increased when it is combined with Mifepristone.
ArformoterolMifepristone may increase the QTc-prolonging activities of Arformoterol.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Mifepristone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Mifepristone.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Mifepristone.
Arsenic trioxideMifepristone may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherMifepristone may increase the QTc-prolonging activities of Artemether.
AsenapineMifepristone may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Mifepristone.
AtazanavirThe serum concentration of Mifepristone can be increased when it is combined with Atazanavir.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Mifepristone.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Mifepristone.
AtomoxetineMifepristone may increase the QTc-prolonging activities of Atomoxetine.
AtomoxetineThe metabolism of Mifepristone can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Mifepristone.
AvanafilThe metabolism of Avanafil can be decreased when combined with Mifepristone.
AxitinibThe metabolism of Axitinib can be decreased when combined with Mifepristone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Mifepristone.
AzithromycinMifepristone may increase the QTc-prolonging activities of Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Mifepristone.
Beclomethasone dipropionateThe therapeutic efficacy of Beclomethasone dipropionate can be decreased when used in combination with Mifepristone.
BedaquilineMifepristone may increase the QTc-prolonging activities of Bedaquiline.
BenmoxinBenmoxin may increase the hypoglycemic activities of Mifepristone.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Mifepristone.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Mifepristone.
BeraprostThe serum concentration of Beraprost can be increased when it is combined with Mifepristone.
BetamethasoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Mifepristone.
BexaroteneThe serum concentration of Mifepristone can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Mifepristone.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Mifepristone.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Mifepristone.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Mifepristone.
BoceprevirThe serum concentration of Mifepristone can be increased when it is combined with Boceprevir.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Mifepristone.
BortezomibThe metabolism of Mifepristone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mifepristone can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Mifepristone.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Mifepristone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Mifepristone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Mifepristone.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Mifepristone.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Mifepristone.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Mifepristone.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Mifepristone.
BudesonideThe metabolism of Budesonide can be decreased when combined with Mifepristone.
BuforminBuformin may increase the hypoglycemic activities of Mifepristone.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Mifepristone.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Mifepristone.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Mifepristone.
BuserelinMifepristone may increase the QTc-prolonging activities of Buserelin.
BuspironeThe metabolism of Buspirone can be decreased when combined with Mifepristone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Mifepristone.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Mifepristone.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Mifepristone.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Mifepristone.
CaffeineThe metabolism of Caffeine can be decreased when combined with Mifepristone.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Mifepristone.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Mifepristone.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Mifepristone.
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Mifepristone.
CandesartanThe serum concentration of Candesartan can be increased when it is combined with Mifepristone.
CarbamazepineThe serum concentration of Mifepristone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Mifepristone.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Mifepristone.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Mifepristone.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Mifepristone.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Mifepristone.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Mifepristone.
CastanospermineCastanospermine may increase the hypoglycemic activities of Mifepristone.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Mifepristone.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Mifepristone.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Mifepristone.
CeritinibMifepristone may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Mifepristone.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Mifepristone.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Mifepristone.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Mifepristone.
ChloroquineMifepristone may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Mifepristone.
ChlorpromazineMifepristone may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Mifepristone.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Mifepristone.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Mifepristone.
CiclesonideThe therapeutic efficacy of Ciclesonide can be decreased when used in combination with Mifepristone.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Mifepristone.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Mifepristone.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Mifepristone.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Mifepristone.
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Mifepristone.
CiprofloxacinMifepristone may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideMifepristone may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Mifepristone.
CitalopramMifepristone may increase the QTc-prolonging activities of Citalopram.
ClarithromycinMifepristone may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Mifepristone can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Mifepristone.
ClobazamThe metabolism of Clobazam can be decreased when combined with Mifepristone.
Clobetasol propionateThe therapeutic efficacy of Clobetasol propionate can be decreased when used in combination with Mifepristone.
ClocortoloneThe therapeutic efficacy of Clocortolone can be decreased when used in combination with Mifepristone.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Mifepristone.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Mifepristone.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Mifepristone.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Mifepristone.
ClomipramineClomipramine may increase the hypoglycemic activities of Mifepristone.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Mifepristone.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Mifepristone.
ClonidineThe metabolism of Clonidine can be decreased when combined with Mifepristone.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Mifepristone.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Mifepristone.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Mifepristone.
ClotrimazoleThe metabolism of Mifepristone can be decreased when combined with Clotrimazole.
ClozapineMifepristone may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Mifepristone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Mifepristone.
CocaineThe metabolism of Cocaine can be decreased when combined with Mifepristone.
CodeineThe metabolism of Codeine can be decreased when combined with Mifepristone.
ColchicineThe metabolism of Colchicine can be decreased when combined with Mifepristone.
ConivaptanThe serum concentration of Mifepristone can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Mifepristone.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Mifepristone.
Cortisone acetateThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Mifepristone.
CrizotinibMifepristone may increase the QTc-prolonging activities of Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Mifepristone.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Mifepristone.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.
CyclosporineThe metabolism of Mifepristone can be decreased when combined with Cyclosporine.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Mifepristone.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone.
DabrafenibThe serum concentration of Mifepristone can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Mifepristone.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Mifepristone.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Mifepristone.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Mifepristone.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Mifepristone.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Mifepristone.
DapoxetineDapoxetine may increase the hypoglycemic activities of Mifepristone.
DapsoneThe metabolism of Dapsone can be decreased when combined with Mifepristone.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Mifepristone.
DarunavirThe serum concentration of Mifepristone can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Mifepristone.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Mifepristone.
DasatinibThe serum concentration of Mifepristone can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Mifepristone.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Mifepristone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Mifepristone.
DeferasiroxThe serum concentration of Mifepristone can be decreased when it is combined with Deferasirox.
DegarelixMifepristone may increase the QTc-prolonging activities of Degarelix.
DehydroepiandrosteroneThe therapeutic efficacy of Dehydroepiandrosterone can be decreased when used in combination with Mifepristone.
dehydroepiandrosterone sulfateThe therapeutic efficacy of dehydroepiandrosterone sulfate can be decreased when used in combination with Mifepristone.
DelavirdineThe metabolism of Mifepristone can be decreased when combined with Delavirdine.
DesfluraneMifepristone may increase the QTc-prolonging activities of Desflurane.
DesipramineMifepristone may increase the QTc-prolonging activities of Desipramine.
DesoximetasoneThe therapeutic efficacy of Desoximetasone can be decreased when used in combination with Mifepristone.
Desoxycorticosterone acetateThe therapeutic efficacy of Desoxycorticosterone acetate can be decreased when used in combination with Mifepristone.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Mifepristone.
DexamethasoneThe therapeutic efficacy of Dexamethasone can be decreased when used in combination with Mifepristone.
DexamethasoneThe serum concentration of Mifepristone can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe therapeutic efficacy of Dexamethasone isonicotinate can be decreased when used in combination with Mifepristone.
DexketoprofenThe therapeutic efficacy of Mifepristone can be decreased when used in combination with Dexketoprofen.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Mifepristone.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Mifepristone.
DiazepamThe metabolism of Diazepam can be decreased when combined with Mifepristone.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Mifepristone.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Mifepristone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mifepristone.
DiflorasoneThe therapeutic efficacy of Diflorasone can be decreased when used in combination with Mifepristone.
DiflunisalDiflunisal may increase the hypoglycemic activities of Mifepristone.
DifluocortoloneThe therapeutic efficacy of Difluocortolone can be decreased when used in combination with Mifepristone.
DifluprednateThe therapeutic efficacy of Difluprednate can be decreased when used in combination with Mifepristone.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Mifepristone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mifepristone.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Mifepristone.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Mifepristone.
DihydroergotamineThe metabolism of Mifepristone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Mifepristone.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Mifepristone.
DiltiazemThe metabolism of Mifepristone can be decreased when combined with Diltiazem.
DiphenhydramineMifepristone may increase the QTc-prolonging activities of Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Mifepristone.
DisopyramideMifepristone may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Mifepristone.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Mifepristone.
DofetilideMifepristone may increase the QTc-prolonging activities of Dofetilide.
DolasetronMifepristone may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Mifepristone.
DomperidoneDomperidone may increase the QTc-prolonging activities of Mifepristone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Mifepristone.
DopamineThe serum concentration of Dopamine can be increased when it is combined with Mifepristone.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Mifepristone.
DoxepinThe metabolism of Doxepin can be decreased when combined with Mifepristone.
DoxepinDoxepin may increase the QTc-prolonging activities of Mifepristone.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Mifepristone.
DoxycyclineThe metabolism of Mifepristone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Mifepristone.
DronedaroneMifepristone may increase the QTc-prolonging activities of Dronedarone.
DroperidolMifepristone may increase the QTc-prolonging activities of Droperidol.
DulaglutideDulaglutide may increase the hypoglycemic activities of Mifepristone.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Mifepristone.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Mifepristone.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Mifepristone.
EfavirenzThe serum concentration of Mifepristone can be decreased when it is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Mifepristone.
EliglustatMifepristone may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Mifepristone.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Mifepristone.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Mifepristone.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Mifepristone.
EnzalutamideThe serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Mifepristone.
EpinastineThe metabolism of Epinastine can be decreased when combined with Mifepristone.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Mifepristone.
EpoprostenolThe serum concentration of Epoprostenol can be increased when it is combined with Mifepristone.
EquileninThe therapeutic efficacy of Equilenin can be decreased when used in combination with Mifepristone.
EquilinThe therapeutic efficacy of Equilin can be decreased when used in combination with Mifepristone.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Mifepristone.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Mifepristone.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Mifepristone.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Mifepristone.
EribulinMifepristone may increase the QTc-prolonging activities of Eribulin.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Mifepristone.
ErythromycinMifepristone may increase the QTc-prolonging activities of Erythromycin.
EscitalopramMifepristone may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Mifepristone can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Mifepristone.
EstazolamThe metabolism of Estazolam can be decreased when combined with Mifepristone.
EstradiolThe metabolism of Estradiol can be decreased when combined with Mifepristone.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Mifepristone.
EstramustineThe metabolism of Estramustine can be decreased when combined with Mifepristone.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Mifepristone.
EstroneThe therapeutic efficacy of Estrone can be decreased when used in combination with Mifepristone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Mifepristone.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Mifepristone.
EthanolThe metabolism of Ethanol can be decreased when combined with Mifepristone.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Mifepristone.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Mifepristone.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Mifepristone.
EtodolacThe serum concentration of Etodolac can be increased when it is combined with Mifepristone.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Mifepristone.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Mifepristone.
EtoposideThe metabolism of Etoposide can be decreased when combined with Mifepristone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Mifepristone.
EtravirineThe serum concentration of Mifepristone can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Mifepristone.
EverolimusThe metabolism of Everolimus can be decreased when combined with Mifepristone.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Mifepristone.
ExenatideExenatide may increase the hypoglycemic activities of Mifepristone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Mifepristone.
EzogabineMifepristone may increase the QTc-prolonging activities of Ezogabine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Mifepristone.
FamotidineMifepristone may increase the QTc-prolonging activities of Famotidine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Mifepristone.
FelbamateFelbamate may increase the QTc-prolonging activities of Mifepristone.
FelodipineThe metabolism of Felodipine can be decreased when combined with Mifepristone.
FenfluramineFenfluramine may increase the hypoglycemic activities of Mifepristone.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Mifepristone.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Mifepristone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mifepristone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Mifepristone.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Mifepristone.
FinasterideThe metabolism of Finasteride can be decreased when combined with Mifepristone.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Mifepristone.
FingolimodFingolimod may increase the QTc-prolonging activities of Mifepristone.
FlecainideMifepristone may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Mifepristone.
FluconazoleMifepristone may increase the QTc-prolonging activities of Fluconazole.
FluconazoleThe metabolism of Mifepristone can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Fludrocortisone can be decreased when used in combination with Mifepristone.
FlumethasoneThe therapeutic efficacy of Flumethasone can be decreased when used in combination with Mifepristone.
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Mifepristone.
FlunisolideThe therapeutic efficacy of Flunisolide can be decreased when used in combination with Mifepristone.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Mifepristone.
Fluocinolone AcetonideThe therapeutic efficacy of Fluocinolone Acetonide can be decreased when used in combination with Mifepristone.
FluocinonideThe therapeutic efficacy of Fluocinonide can be decreased when used in combination with Mifepristone.
FluocortoloneThe therapeutic efficacy of Fluocortolone can be decreased when used in combination with Mifepristone.
FluorometholoneThe therapeutic efficacy of Fluorometholone can be decreased when used in combination with Mifepristone.
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Mifepristone.
FluoxetineMifepristone may increase the QTc-prolonging activities of Fluoxetine.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Mifepristone.
FlupentixolMifepristone may increase the QTc-prolonging activities of Flupentixol.
FluprednideneThe therapeutic efficacy of Fluprednidene can be decreased when used in combination with Mifepristone.
FluprednisoloneThe therapeutic efficacy of Fluprednisolone can be decreased when used in combination with Mifepristone.
FlurandrenolideThe therapeutic efficacy of Flurandrenolide can be decreased when used in combination with Mifepristone.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Mifepristone.
FlurbiprofenThe serum concentration of Flurbiprofen can be increased when it is combined with Mifepristone.
FlutamideThe metabolism of Flutamide can be decreased when combined with Mifepristone.
Fluticasone furoateThe therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Mifepristone.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Mifepristone.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Mifepristone.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Mifepristone.
FormoterolMifepristone may increase the QTc-prolonging activities of Formoterol.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Mifepristone.
FosaprepitantThe serum concentration of Mifepristone can be increased when it is combined with Fosaprepitant.
FoscarnetMifepristone may increase the QTc-prolonging activities of Foscarnet.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Mifepristone.
FosphenytoinThe serum concentration of Mifepristone can be decreased when it is combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Mifepristone.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Mifepristone.
Fusidic AcidThe serum concentration of Mifepristone can be increased when it is combined with Fusidic Acid.
Gadobenic acidMifepristone may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Mifepristone.
GalantamineGalantamine may increase the QTc-prolonging activities of Mifepristone.
GavestinelThe serum concentration of Gavestinel can be increased when it is combined with Mifepristone.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Mifepristone.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Mifepristone.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Mifepristone.
GemifloxacinMifepristone may increase the QTc-prolonging activities of Gemifloxacin.
GlibornurideGlibornuride may increase the hypoglycemic activities of Mifepristone.
GliclazideGliclazide may increase the hypoglycemic activities of Mifepristone.
GlimepirideGlimepiride may increase the hypoglycemic activities of Mifepristone.
GlipizideGlipizide may increase the hypoglycemic activities of Mifepristone.
GliquidoneGliquidone may increase the hypoglycemic activities of Mifepristone.
GlyburideGlyburide may increase the hypoglycemic activities of Mifepristone.
GoserelinMifepristone may increase the QTc-prolonging activities of Goserelin.
GranisetronMifepristone may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Mifepristone.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Mifepristone.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Mifepristone.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Mifepristone.
HaloperidolMifepristone may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Mifepristone.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Mifepristone.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Mifepristone.
HistrelinMifepristone may increase the QTc-prolonging activities of Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Mifepristone.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.
HydrocortisoneThe therapeutic efficacy of Hydrocortisone can be decreased when used in combination with Mifepristone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Mifepristone.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Mifepristone.
HydroxyzineMifepristone may increase the QTc-prolonging activities of Hydroxyzine.
IbandronateMifepristone may increase the QTc-prolonging activities of Ibandronate.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Mifepristone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Mifepristone.
IbutilideMifepristone may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Mifepristone.
IdelalisibThe serum concentration of Mifepristone can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Mifepristone.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Mifepristone resulting in a loss in efficacy.
IloperidoneMifepristone may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Mifepristone.
ImatinibThe metabolism of Mifepristone can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Mifepristone.
ImipramineImipramine may increase the QTc-prolonging activities of Mifepristone.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Mifepristone.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Mifepristone.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Mifepristone.
IndalpineIndalpine may increase the hypoglycemic activities of Mifepristone.
IndapamideThe metabolism of Indapamide can be decreased when combined with Mifepristone.
IndapamideIndapamide may increase the QTc-prolonging activities of Mifepristone.
IndinavirThe serum concentration of Mifepristone can be increased when it is combined with Indinavir.
IndinavirThe metabolism of Indinavir can be decreased when combined with Mifepristone.
indisulamThe serum concentration of indisulam can be increased when it is combined with Mifepristone.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Mifepristone.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Mifepristone.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Mifepristone.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Mifepristone.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Mifepristone.
Insulin HumanInsulin Human may increase the hypoglycemic activities of Mifepristone.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Mifepristone.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Mifepristone.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Mifepristone.
IproclozideIproclozide may increase the hypoglycemic activities of Mifepristone.
IproniazidIproniazid may increase the hypoglycemic activities of Mifepristone.
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Mifepristone.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Mifepristone.
IsavuconazoniumThe metabolism of Mifepristone can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Mifepristone.
IsofluraneMifepristone may increase the QTc-prolonging activities of Isoflurane.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Mifepristone.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Mifepristone.
IsradipineThe metabolism of Mifepristone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Mifepristone can be increased when it is combined with Itraconazole.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Mifepristone.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Mifepristone.
IvabradineIvabradine may increase the QTc-prolonging activities of Mifepristone.
IvacaftorThe serum concentration of Mifepristone can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Mifepristone.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Mifepristone.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Mifepristone.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Mifepristone.
KetamineThe metabolism of Ketamine can be decreased when combined with Mifepristone.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Mifepristone.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Mifepristone.
KetoconazoleThe serum concentration of Mifepristone can be increased when it is combined with Ketoconazole.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Mifepristone.
KetoprofenThe serum concentration of Ketoprofen can be increased when it is combined with Mifepristone.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Mifepristone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Mifepristone.
LanreotideMifepristone may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Mifepristone.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Mifepristone.
LapatinibLapatinib may increase the QTc-prolonging activities of Mifepristone.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Mifepristone.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Mifepristone.
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Mifepristone.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Mifepristone.
LenvatinibMifepristone may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Mifepristone.
LesinuradThe serum concentration of Lesinurad can be increased when it is combined with Mifepristone.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Mifepristone.
LeuprolideMifepristone may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Mifepristone.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Mifepristone.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Mifepristone.
LevofloxacinMifepristone may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Mifepristone.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Mifepristone.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Mifepristone.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Mifepristone.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Mifepristone.
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Mifepristone.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Mifepristone.
LinagliptinLinagliptin may increase the hypoglycemic activities of Mifepristone.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Mifepristone.
LiraglutideLiraglutide may increase the hypoglycemic activities of Mifepristone.
LisurideThe metabolism of Lisuride can be decreased when combined with Mifepristone.
LithiumMifepristone may increase the QTc-prolonging activities of Lithium.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Mifepristone.
LoperamideThe metabolism of Loperamide can be decreased when combined with Mifepristone.
LopinavirMifepristone may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Mifepristone.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Mifepristone.
LornoxicamThe serum concentration of Lornoxicam can be increased when it is combined with Mifepristone.
LosartanThe metabolism of Losartan can be decreased when combined with Mifepristone.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Mifepristone.
LovastatinThe metabolism of Mifepristone can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Mifepristone.
LuliconazoleThe serum concentration of Mifepristone can be increased when it is combined with Luliconazole.
LumefantrineMifepristone may increase the QTc-prolonging activities of Lumefantrine.
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Mifepristone.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Mifepristone.
MacitentanThe metabolism of Macitentan can be decreased when combined with Mifepristone.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Mifepristone.
MaprotilineMifepristone may increase the QTc-prolonging activities of Maprotiline.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Mifepristone.
MebanazineMebanazine may increase the hypoglycemic activities of Mifepristone.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Mifepristone.
MecaserminMifepristone may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Mifepristone.
MedrysoneThe therapeutic efficacy of Medrysone can be decreased when used in combination with Mifepristone.
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Mifepristone.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Mifepristone.
MefloquineMefloquine may increase the QTc-prolonging activities of Mifepristone.
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Mifepristone.
MelengestrolThe therapeutic efficacy of Melengestrol can be decreased when used in combination with Mifepristone.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Mifepristone.
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Mifepristone.
MesalazineMesalazine may increase the hypoglycemic activities of Mifepristone.
MestranolThe serum concentration of Mestranol can be increased when it is combined with Mifepristone.
MetforminMetformin may increase the hypoglycemic activities of Mifepristone.
MethadoneMifepristone may increase the QTc-prolonging activities of Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Mifepristone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Mifepristone.
MethotrimeprazineMifepristone may increase the QTc-prolonging activities of Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Mifepristone.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Mifepristone.
Methylene blueMethylene blue may increase the hypoglycemic activities of Mifepristone.
MethylprednisoloneThe therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Mifepristone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Mifepristone.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Mifepristone.
MetoclopramideMifepristone may increase the QTc-prolonging activities of Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Mifepristone.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Mifepristone.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Mifepristone.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Mifepristone.
MianserinThe metabolism of Mianserin can be decreased when combined with Mifepristone.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Mifepristone.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Mifepristone.
MidazolamThe metabolism of Midazolam can be decreased when combined with Mifepristone.
MiglitolMiglitol may increase the hypoglycemic activities of Mifepristone.
MiglustatMiglustat may increase the hypoglycemic activities of Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Mifepristone.
MinaprineMinaprine may increase the hypoglycemic activities of Mifepristone.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Mifepristone.
MirabegronMirabegron may increase the QTc-prolonging activities of Mifepristone.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Mifepristone.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Mifepristone.
MitiglinideMitiglinide may increase the hypoglycemic activities of Mifepristone.
MitotaneThe serum concentration of Mifepristone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Mifepristone.
MoclobemideThe serum concentration of Moclobemide can be increased when it is combined with Mifepristone.
MoclobemideMoclobemide may increase the hypoglycemic activities of Mifepristone.
ModafinilThe serum concentration of Mifepristone can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Mifepristone.
MoexiprilMifepristone may increase the QTc-prolonging activities of Moexipril.
MometasoneThe therapeutic efficacy of Mometasone can be decreased when used in combination with Mifepristone.
MontelukastThe metabolism of Montelukast can be decreased when combined with Mifepristone.
MorphineThe metabolism of Morphine can be decreased when combined with Mifepristone.
MoxifloxacinMifepristone may increase the QTc-prolonging activities of Moxifloxacin.
muraglitazarThe serum concentration of muraglitazar can be increased when it is combined with Mifepristone.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Mifepristone.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Mifepristone.
NafcillinThe serum concentration of Mifepristone can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Mifepristone.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Mifepristone.
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Mifepristone.
NateglinideNateglinide may increase the hypoglycemic activities of Mifepristone.
NefazodoneThe serum concentration of Mifepristone can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Mifepristone.
NelfinavirThe serum concentration of Mifepristone can be increased when it is combined with Nelfinavir.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Mifepristone.
NetupitantThe serum concentration of Mifepristone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Mifepristone can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Mifepristone.
NialamideNialamide may increase the hypoglycemic activities of Mifepristone.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Mifepristone.
NicardipineNicardipine may increase the QTc-prolonging activities of Mifepristone.
NiclosamideThe serum concentration of Niclosamide can be increased when it is combined with Mifepristone.
NicotineThe metabolism of Nicotine can be decreased when combined with Mifepristone.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Mifepristone.
NilotinibMifepristone may increase the QTc-prolonging activities of Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Mifepristone.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Mifepristone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Mifepristone.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Mifepristone.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Mifepristone.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Mifepristone.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Mifepristone.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Mifepristone.
NorfloxacinMifepristone may increase the QTc-prolonging activities of Norfloxacin.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Mifepristone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Mifepristone.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Mifepristone.
OctamoxinOctamoxin may increase the hypoglycemic activities of Mifepristone.
OctreotideOctreotide may increase the hypoglycemic activities of Mifepristone.
OfloxacinMifepristone may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the hypoglycemic activities of Mifepristone.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Mifepristone.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Mifepristone.
OlaparibThe metabolism of Mifepristone can be decreased when combined with Olaparib.
OlodaterolMifepristone may increase the QTc-prolonging activities of Olodaterol.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Mifepristone.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Mifepristone.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Mifepristone.
OndansetronMifepristone may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Mifepristone.
OsimertinibThe serum concentration of Mifepristone can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Mifepristone.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Mifepristone.
OxandroloneOxandrolone may increase the hypoglycemic activities of Mifepristone.
OxaprozinThe serum concentration of Oxaprozin can be increased when it is combined with Mifepristone.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Mifepristone.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Mifepristone.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Mifepristone.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Mifepristone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Mifepristone.
OxytocinMifepristone may increase the QTc-prolonging activities of Oxytocin.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Mifepristone.
PalbociclibThe serum concentration of Mifepristone can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Mifepristone.
PaliperidoneMifepristone may increase the QTc-prolonging activities of Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Mifepristone.
PanobinostatMifepristone may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Mifepristone.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Mifepristone.
ParamethasoneThe therapeutic efficacy of Paramethasone can be decreased when used in combination with Mifepristone.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Mifepristone.
PargylinePargyline may increase the hypoglycemic activities of Mifepristone.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Mifepristone.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Mifepristone.
ParoxetineMifepristone may increase the QTc-prolonging activities of Paroxetine.
ParoxetineParoxetine may increase the hypoglycemic activities of Mifepristone.
PasireotideMifepristone may increase the hypoglycemic activities of Pasireotide.
PazopanibMifepristone may increase the QTc-prolonging activities of Pazopanib.
PegvisomantPegvisomant may increase the hypoglycemic activities of Mifepristone.
PentamidineMifepristone may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe serum concentration of Mifepristone can be decreased when it is combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Mifepristone.
PerflutrenMifepristone may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Mifepristone.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Mifepristone.
PermethrinThe metabolism of Permethrin can be decreased when combined with Mifepristone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Mifepristone.
PethidineThe metabolism of Pethidine can be decreased when combined with Mifepristone.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Mifepristone.
PhenelzinePhenelzine may increase the hypoglycemic activities of Mifepristone.
PhenforminPhenformin may increase the hypoglycemic activities of Mifepristone.
PheniprazinePheniprazine may increase the hypoglycemic activities of Mifepristone.
PhenobarbitalThe serum concentration of Mifepristone can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Mifepristone.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Mifepristone.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Mifepristone.
PhenylbutazoneThe serum concentration of Phenylbutazone can be increased when it is combined with Mifepristone.
PhenytoinThe serum concentration of Mifepristone can be decreased when it is combined with Phenytoin.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Mifepristone.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Mifepristone.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Mifepristone.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Mifepristone.
PimozidePimozide may increase the QTc-prolonging activities of Mifepristone.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Mifepristone.
PioglitazonePioglitazone may increase the hypoglycemic activities of Mifepristone.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Mifepristone.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Mifepristone.
PirlindolePirlindole may increase the hypoglycemic activities of Mifepristone.
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Mifepristone.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Mifepristone.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Mifepristone.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Mifepristone.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Mifepristone.
PosaconazoleThe serum concentration of Mifepristone can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Mifepristone.
PramlintidePramlintide may increase the hypoglycemic activities of Mifepristone.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Mifepristone.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Mifepristone.
PrazepamThe metabolism of Prazepam can be decreased when combined with Mifepristone.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Mifepristone.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Mifepristone.
PrednicarbateThe therapeutic efficacy of Prednicarbate can be decreased when used in combination with Mifepristone.
PrednisoloneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.
PrednisoneThe therapeutic efficacy of Prednisone can be decreased when used in combination with Mifepristone.
PregnenoloneThe therapeutic efficacy of Pregnenolone can be decreased when used in combination with Mifepristone.
PrimaquineMifepristone may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Mifepristone can be decreased when it is combined with Primidone.
ProcainamideMifepristone may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Mifepristone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Mifepristone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Mifepristone.
PromazineMifepristone may increase the QTc-prolonging activities of Promazine.
PromethazineMifepristone may increase the QTc-prolonging activities of Promethazine.
PropafenoneMifepristone may increase the QTc-prolonging activities of Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Mifepristone.
PropofolPropofol may increase the QTc-prolonging activities of Mifepristone.
PropranololThe metabolism of Propranolol can be decreased when combined with Mifepristone.
ProtriptylineMifepristone may increase the QTc-prolonging activities of Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Mifepristone.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Mifepristone.
QuazepamThe metabolism of Quazepam can be decreased when combined with Mifepristone.
QuetiapineMifepristone may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Mifepristone.
QuinidineMifepristone may increase the QTc-prolonging activities of Quinidine.
QuinineMifepristone may increase the QTc-prolonging activities of Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Mifepristone.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Mifepristone.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Mifepristone.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Mifepristone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Mifepristone.
RanolazineThe metabolism of Mifepristone can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypoglycemic activities of Mifepristone.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Mifepristone.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Mifepristone.
RepaglinideRepaglinide may increase the hypoglycemic activities of Mifepristone.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Mifepristone.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Mifepristone.
RifabutinThe serum concentration of Mifepristone can be decreased when it is combined with Rifabutin.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Mifepristone.
RifampicinThe serum concentration of Mifepristone can be decreased when it is combined with Rifampicin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Mifepristone.
RifapentineThe serum concentration of Mifepristone can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Mifepristone.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Mifepristone.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Mifepristone.
RimexoloneThe therapeutic efficacy of Rimexolone can be decreased when used in combination with Mifepristone.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Mifepristone.
RiociguatThe metabolism of Riociguat can be decreased when combined with Mifepristone.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Mifepristone.
RisperidoneRisperidone may increase the QTc-prolonging activities of Mifepristone.
RitonavirThe serum concentration of Mifepristone can be increased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Mifepristone.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Mifepristone.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Mifepristone.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Mifepristone.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Mifepristone.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Mifepristone.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Mifepristone.
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Mifepristone.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Mifepristone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Mifepristone.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Mifepristone.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Mifepristone.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Mifepristone.
SafrazineSafrazine may increase the hypoglycemic activities of Mifepristone.
SalbutamolMifepristone may increase the QTc-prolonging activities of Salbutamol.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Mifepristone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Mifepristone.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Mifepristone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Mifepristone.
SaquinavirMifepristone may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Mifepristone.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Mifepristone.
SelegilineSelegiline may increase the hypoglycemic activities of Mifepristone.
SelegilineThe metabolism of Selegiline can be decreased when combined with Mifepristone.
SelexipagThe metabolism of Selexipag can be decreased when combined with Mifepristone.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Mifepristone.
SertindoleThe metabolism of Sertindole can be decreased when combined with Mifepristone.
SertralineSertraline may increase the hypoglycemic activities of Mifepristone.
SertralineThe metabolism of Sertraline can be decreased when combined with Mifepristone.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Mifepristone.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Mifepristone.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Mifepristone.
SildenafilThe metabolism of Mifepristone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.
SiltuximabThe serum concentration of Mifepristone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mifepristone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Mifepristone.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Mifepristone.
SitagliptinSitagliptin may increase the hypoglycemic activities of Mifepristone.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Mifepristone.
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Mifepristone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Mifepristone.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Mifepristone.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Mifepristone.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Mifepristone.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Mifepristone.
SorafenibSorafenib may increase the QTc-prolonging activities of Mifepristone.
SotalolMifepristone may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Mifepristone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Mifepristone.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Mifepristone.
St. John's WortThe serum concentration of Mifepristone can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hypoglycemic activities of Mifepristone.
StiripentolThe serum concentration of Mifepristone can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Mifepristone.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Mifepristone.
SulfamethoxazoleMifepristone may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamoxoleThe serum concentration of Sulfamoxole can be increased when it is combined with Mifepristone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Mifepristone.
SulfisoxazoleMifepristone may increase the QTc-prolonging activities of Sulfisoxazole.
SulodexideSulodexide may increase the hypoglycemic activities of Mifepristone.
SunitinibMifepristone may increase the hypoglycemic activities of Sunitinib.
SuprofenThe serum concentration of Suprofen can be increased when it is combined with Mifepristone.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Mifepristone.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Mifepristone.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Mifepristone.
TacrolimusMifepristone may increase the QTc-prolonging activities of Tacrolimus.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Mifepristone.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Mifepristone.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Mifepristone.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Mifepristone.
TapentadolThe serum concentration of Tapentadol can be increased when it is combined with Mifepristone.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Mifepristone.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Mifepristone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Mifepristone.
TazaroteneThe serum concentration of Tazarotene can be increased when it is combined with Mifepristone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Mifepristone.
TelaprevirThe serum concentration of Mifepristone can be increased when it is combined with Telaprevir.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Mifepristone.
TelavancinMifepristone may increase the QTc-prolonging activities of Telavancin.
TelithromycinMifepristone may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Mifepristone.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Mifepristone.
TeniposideThe metabolism of Teniposide can be decreased when combined with Mifepristone.
TenoxicamThe serum concentration of Tenoxicam can be increased when it is combined with Mifepristone.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Mifepristone.
TerbutalineMifepristone may increase the QTc-prolonging activities of Terbutaline.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Mifepristone.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Mifepristone.
TestosteroneTestosterone may increase the hypoglycemic activities of Mifepristone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Mifepristone.
TetrabenazineMifepristone may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Mifepristone.
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Mifepristone.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Mifepristone.
ThiamylalThe serum concentration of Thiamylal can be increased when it is combined with Mifepristone.
ThioridazineMifepristone may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Mifepristone.
ThiothixeneMifepristone may increase the QTc-prolonging activities of Thiothixene.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Mifepristone.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Mifepristone.
TiclopidineThe metabolism of Mifepristone can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Mifepristone.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Mifepristone.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Mifepristone.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Mifepristone.
TixocortolThe therapeutic efficacy of Tixocortol can be decreased when used in combination with Mifepristone.
TizanidineMifepristone may increase the QTc-prolonging activities of Tizanidine.
TocilizumabThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Mifepristone.
TolazamideTolazamide may increase the hypoglycemic activities of Mifepristone.
TolbutamideTolbutamide may increase the hypoglycemic activities of Mifepristone.
ToloxatoneToloxatone may increase the hypoglycemic activities of Mifepristone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Mifepristone.
TolterodineTolterodine may increase the QTc-prolonging activities of Mifepristone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Mifepristone.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Mifepristone.
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.
ToremifeneMifepristone may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Mifepristone.
TramadolThe metabolism of Tramadol can be decreased when combined with Mifepristone.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Mifepristone.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Mifepristone.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Mifepristone.
TrazodoneTrazodone may increase the hypoglycemic activities of Mifepristone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Mifepristone.
TreprostinilMifepristone may increase the QTc-prolonging activities of Treprostinil.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Mifepristone.
TriamcinoloneThe therapeutic efficacy of Triamcinolone can be decreased when used in combination with Mifepristone.
TriazolamThe metabolism of Triazolam can be decreased when combined with Mifepristone.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Mifepristone.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Mifepristone.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Mifepristone.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Mifepristone.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Mifepristone.
TriptorelinMifepristone may increase the QTc-prolonging activities of Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Mifepristone.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Mifepristone.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Mifepristone.
UdenafilThe metabolism of Udenafil can be decreased when combined with Mifepristone.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Mifepristone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Mifepristone.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Mifepristone.
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Mifepristone.
ValsartanThe serum concentration of Valsartan can be increased when it is combined with Mifepristone.
VandetanibMifepristone may increase the QTc-prolonging activities of Vandetanib.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Mifepristone.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Mifepristone.
VardenafilVardenafil may increase the QTc-prolonging activities of Mifepristone.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Mifepristone.
VemurafenibMifepristone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Mifepristone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Mifepristone can be decreased when combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Mifepristone.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Mifepristone.
VilanterolVilanterol may increase the QTc-prolonging activities of Mifepristone.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Mifepristone.
VilazodoneVilazodone may increase the hypoglycemic activities of Mifepristone.
VildagliptinVildagliptin may increase the hypoglycemic activities of Mifepristone.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Mifepristone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Mifepristone.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Mifepristone.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Mifepristone.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Mifepristone.
VogliboseVoglibose may increase the hypoglycemic activities of Mifepristone.
VoriconazoleThe serum concentration of Mifepristone can be increased when it is combined with Voriconazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Mifepristone.
VorinostatMifepristone may increase the QTc-prolonging activities of Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Mifepristone.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Mifepristone.
WarfarinThe metabolism of Warfarin can be decreased when combined with Mifepristone.
XimelagatranThe serum concentration of Ximelagatran can be increased when it is combined with Mifepristone.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Mifepristone.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Mifepristone.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Mifepristone.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Mifepristone.
ZaltoprofenThe serum concentration of Zaltoprofen can be increased when it is combined with Mifepristone.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Mifepristone.
ZileutonThe metabolism of Zileuton can be decreased when combined with Mifepristone.
ZimelidineZimelidine may increase the hypoglycemic activities of Mifepristone.
ZiprasidoneMifepristone may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Mifepristone.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Mifepristone.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Mifepristone.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Mifepristone.
ZuclopenthixolMifepristone may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Greb RR, Kiesel L, Selbmann AK, Wehrmann M, Hodgen GD, Goodman AL, Wallwiener D: Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Hum Reprod. 1999 Jan;14(1):198-206. [PubMed:10374120 ]
  2. Sun M, Zhu G, Zhou L: [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata]. Zhonghua Fu Chan Ke Za Zhi. 1998 Apr;33(4):227-31. [PubMed:10682471 ]
  3. Hazra BG, Basu S, Pore VS, Joshi PL, Pal D, Chakrabarti P: Synthesis of 11beta-(4-dimethylaminophenyl)-17beta-hydroxy-17alpha- (3-methyl-1-butynyl)-4, 9-estradien-3-one and 11beta-(4-acetophenyl)- 17beta-hydroxy-17alpha-(3-methyl-1-butynyl)-4, 9-estradien-3-one: two new analogs of mifepristone (RU-486). Steroids. 2000 Mar;65(3):157-62. [PubMed:10699595 ]
  4. Gao Y, Cheng L, Liu Y: [Failure of mifepristone induced interruption of pregnancy: point mutation at genetic codon 722 in human progesterone receptor gene]. Zhonghua Fu Chan Ke Za Zhi. 1998 Sep;33(9):549-52. [PubMed:10806733 ]
  5. Jiang J, Wu R, Wang Z: [Effects of mifepristone on expression of estrogen receptor and progesterone receptor in cultured human eutopic and ectopic endometria]. Zhonghua Fu Chan Ke Za Zhi. 2001 Apr;36(4):218-21. [PubMed:11783365 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. LeVan TD, Babin EA, Yamamura HI, Bloom JW: Pharmacological characterization of glucocorticoid receptors in primary human bronchial epithelial cells. Biochem Pharmacol. 1999 May 1;57(9):1003-9. [PubMed:10796070 ]
  2. Attardi BJ, Burgenson J, Hild SA, Reel JR: In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88. [PubMed:15120421 ]
  3. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [PubMed:15336699 ]
  4. Gu G, Hentunen TA, Nars M, Harkonen PL, Vaananen HK: Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis. 2005 May;10(3):583-95. [PubMed:15909120 ]
  5. de Pablos RM, Villaran RF, Arguelles S, Herrera AJ, Venero JL, Ayala A, Cano J, Machado A: Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci. 2006 May 24;26(21):5709-19. [PubMed:16723527 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 1994 Nov 28;355(2):187-91. [PubMed:7982498 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. [PubMed:10329417 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:17